Digital Pathology News | Tissuepathology.com

Aiforia Announces Webinar for November 4

Erica Goodpaster — Fri, 23 Oct 2026 13:05:08 +0000

AI models in GI/liver pathology using the Aiforia Platform Quantitative and predictive AI models in gastrointestinal and liver pathology: the Mayo Clinic experience 4 November 2026 – 12:00 PM (noon) EST REGISTER NOW Over the past 5 years, researchers and pathologists at Mayo Clinic have spearheaded the development of advanced artificial intelligence (AI) models across […]

The post Aiforia Announces Webinar for November 4 first appeared on Tissuepathology.com.

SimBioSys Secures FDA Clearance for TumorSight® Risk, Introducing the World’s First AI-Powered, MRI-Derived Breast Cancer Recurrence Risk Assessment

Erica Goodpaster — Thu, 22 Oct 2026 16:42:29 +0000

SimBioSys: Novel software transforms routinely collected MRI, pathology and clinical data into personalized five- and ten-year recurrence risk insight for women with early-stage breast cancer CHICAGO, IL – October 15, 2026 – SimBioSys®, an AI-driven precision medicine company revolutionizing how cancer is understood and treated, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance […]

The post SimBioSys Secures FDA Clearance for TumorSight® Risk, Introducing the World’s First AI-Powered, MRI-Derived Breast Cancer Recurrence Risk Assessment first appeared on Tissuepathology.com.

Indica Labs Announces Webinar for November

Erica Goodpaster — Wed, 21 Oct 2026 10:51:31 +0000

Indica Labs: Learn About AI Model Interoperability with HALO AI Open AI Workflows in Digital Pathology: Model Interoperability with HALO® Date: 4 November 2026 Time: 8:00 – 9:00 PST | 11:00 – 12:00 EST | 16:00 – 17:00 GMT Location: Webinar Register Now Summary As artificial intelligence becomes increasingly integrated into digital pathology, interoperability between […]

The post Indica Labs Announces Webinar for November first appeared on Tissuepathology.com.

HistoIndex and A*STAR Partner To Advance Early – Stage Development Of Pipeline Therapies For Fibrotic Diseases

Erica Goodpaster — Tue, 20 Oct 2026 12:52:38 +0000

[SINGAPORE, October 19th, 2026] – /PR Newswire/ HistoIndex, a pioneer in AI-driven digital pathology for fibrotic diseases, and the Agency for Science, Technology and Research (A*STAR), Singapore’s lead public sector R&D agency, have signed a Memorandum of Understanding (MoU) to collaborate on the preclinical evaluation and characterization of therapeutic candidates for various fibrotic diseases, including […]

The post HistoIndex and A*STAR Partner To Advance Early – Stage Development Of Pipeline Therapies For Fibrotic Diseases first appeared on Tissuepathology.com.

Tempus Presents Data Demonstrating AI-Enabled Pre-Screening Can Help Identify Patients for Biomarker Testing in NSCLC

Erica Goodpaster — Mon, 19 Oct 2026 12:41:31 +0000

Tempus: Study presented at ESMO evaluated more than 60,000 advanced NSCLC cases and found greater than 80% sensitivity across all 12 biomarkers using routine H&E pathology images CHICAGO–(BUSINESS WIRE)–Tempus AI, Inc. (NASDAQ: TEM) today announced results from a study evaluating an AI-enabled pre-screening panel for patients with advanced non-small cell lung cancer (NSCLC). The panel […]

The post Tempus Presents Data Demonstrating AI-Enabled Pre-Screening Can Help Identify Patients for Biomarker Testing in NSCLC first appeared on Tissuepathology.com.

Deciphex CEO at International AI Summit in Dublin

Erica Goodpaster — Fri, 16 Oct 2026 11:51:30 +0000

From Deciphex on LinkedIn: Our founder and CEO Donal O’Shea was on stage at the International AI Summit in Dublin yesterday, the flagship AI event of Ireland’s EU Council Presidency. He joined Áine Kerr, Dorothy Creaven (Jentic), Eoin Hinchy (Tines) and Guillaume Princen (Anthropic) on the panel “Developing Global AI Leaders: From Start-ups to Scale-ups”. […]

The post Deciphex CEO at International AI Summit in Dublin first appeared on Tissuepathology.com.